Physician profile
Mark A Coan
NPI 1689698599
$12,999.04
in general payments reported to CMS, 2019-2025
33 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $718 · 2021: $1,622 · 2022: $1,522 · 2023: $1,357 · 2024: $4,052 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,659 · Travel and Lodging: $1,604 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $400 · Entertainment: $194 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,659.32 |
| Travel and Lodging | $1,604.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $400.00 |
| Entertainment | $194.29 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,765.09 | 2019-2025 | Cvi Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $2,211.88 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $1,164.23 | 2019-2025 | Dailies Total1, Precision7, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $833.43 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $483.73 | 2019-2025 | Acuvue |
| The Walman Optical Company | $480.00 | 2020 | |
| Oyster Point Pharma, INC. | $414.28 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $382.04 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $349.94 | 2021-2022 | |
| Optos, INC. | $348.23 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $342.46 | 2023-2025 | |
| Dompe US, INC. | $255.27 | 2023-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $234.51 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $224.06 | 2019-2023 | Cequa |
| Abbvie INC. | $208.51 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $191.67 | 2021 | |
| Optovue, INC. | $143.55 | 2019-2021 | |
| Lombart Brothers, INC. | $138.32 | 2024 | Opd-III |
| Horizon Therapeutics Plc | $124.97 | 2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $121.84 | 2024 | Syfovre |
| Glaukos Corporation | $113.17 | 2024-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Photrexa |
| Novartis Pharmaceuticals Corporation | $86.97 | 2019-2022 | |
| Rxsight INC | $63.69 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Abb Con-Cise Optical Group LLC | $58.49 | 2025 | Contact Lens |
| Eyevance Pharmaceuticals LLC | $44.04 | 2019-2022 | |
| Maculogix, INC. | $43.01 | 2019 | |
| Visionix USA, INC | $40.00 | 2022 | |
| Notal Vision, INC. | $33.98 | 2024 | Foresee Home |
| Johnson & Johnson Surgical Vision, INC. | $20.76 | 2021 | |
| Biotissue Holdings INC. | $20.07 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $19.55 | 2022 | |
| Sight Sciences, INC. | $18.75 | 2021 | |
| Shire North American Group INC | $18.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Coan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.